Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Raises $46M in Series D Financing

NEW YORK (GenomeWeb) – Quanterix has raised $46 million in Series D funding from new and existing investors.

Three new investors — Trinitas Capital, Cormorant Asset Management, and Arch Overage Fund — led the round with continued participation from existing investors Arch Venture Partners, Bain Capital Ventures, Tufts University, and Quanterix scientific founder David Walt. Hercules Capital also participated in the round.

In a statement, Lexington, Massachusetts-based Quanterix said it would use the proceeds to develop desktop instruments, expand its assay menu for protein and nucleic acid biomarkers, and build global sales. Proceeds will also be used for studies to demonstrate potential applications for Quanterix's single-molecule array technology in drug development, personalized medicine, and diagnostics.

The firm added that it has seen six consecutive quarters of 100 percent growth and is aiming to offer 60 assays by the end of the year. It also intends to ramp up its commercial channel to drive further global expansion, following its move into the Asia Pacific region earlier this year.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.